🧠 Food for thought

Implications, context, and why it matters.

GenSci098 lags in a crowded thyroid eye disease race

• GenSci098 is a subcutaneous (under-the-skin) anti–thyroid-stimulating hormone receptor (TSHR) antibody in Phase 1 testing 1. It trails Amgen’s Tepezza, now approved, plus programs from Viridian Therapeutics and Tourmaline Bio 2.
• The deal value could reach US$1.44 billion 3. There is no late-stage efficacy readout, since the ongoing work is a Phase 1 safety and tolerability study in 76 patients 1.
• More than 20 companies pursue 25-plus thyroid eye disease drugs 2. Viridian’s VRDN-003 aims to finish Phase 3 enrollment by September 2025 2. Alumis has US Food and Drug Administration (FDA) Fast Track for lonigutamab 2, a program that speeds development.
• Argenx, a biopharmaceutical company, halted its Phase 3 efgartigimod trials in thyroid eye disease (TED) for futility 4. The setback signals high clinical risk even for well-funded programs.

Trial service firms can plan for Yarrow’s US and possible Europe push

• Yarrow needs to move GenSci098 from a 76-patient Phase 1 study 1 to larger Phase 2 then Phase 3 trials across North America with potential Europe sites, to support the up to US$1.44 billion deal 13.
• Patient recruiters with thyroid eye disease experience can start outreach now, since US networks are active at centers running Viridian’s Phase 3 2, batoclimab studies 5, VRDN-003, lonigutamab, and satralizumab 5.
• Health data platforms that track Clinical Activity Scores, a clinician-rated inflammation measure, and proptosis, eye bulging, can give Yarrow patient-finding tools tied to onset within 12 months plus symptom thresholds 1.